Kochupurakkal, Bose

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 452

CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA Wild-Type and mutated models of Triple-Negative breast Cancer

Johnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports

PARP inhibition in cancer therapyAdvanced Breast Cancer Therapies

Cited by 291

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 263